X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (5210) 5210
Newsletter (32) 32
Book Chapter (14) 14
Book / eBook (6) 6
Magazine Article (3) 3
Dissertation (2) 2
Newspaper Article (2) 2
Publication (2) 2
Conference Proceeding (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
science & technology (3985) 3985
life sciences & biomedicine (3821) 3821
humans (3812) 3812
male (2428) 2428
animals (2024) 2024
sulfonamides - pharmacokinetics (1964) 1964
pharmacology & pharmacy (1957) 1957
female (1728) 1728
sulfonamides - pharmacology (1666) 1666
sulfonamides - therapeutic use (1394) 1394
sulfonamides - administration & dosage (1344) 1344
adult (1205) 1205
middle aged (1152) 1152
sulfonamides - adverse effects (901) 901
rats (808) 808
aged (759) 759
sulfonamides - chemistry (668) 668
sulfonamides (656) 656
oncology (610) 610
dose-response relationship, drug (582) 582
treatment outcome (579) 579
mice (575) 575
pharmacokinetics (571) 571
sulfonamides - blood (546) 546
administration, oral (523) 523
drug interactions (495) 495
chemistry (494) 494
analysis (477) 477
physical sciences (466) 466
celecoxib (439) 439
drug therapy, combination (429) 429
research (390) 390
pharmacology/toxicology (377) 377
drug therapy (366) 366
medicine & public health (363) 363
sulfonamides - metabolism (346) 346
rats, sprague-dawley (344) 344
care and treatment (343) 343
rosuvastatin calcium (336) 336
area under curve (333) 333
cell line, tumor (331) 331
biochemistry & molecular biology (326) 326
structure-activity relationship (322) 322
young adult (302) 302
pyrimidines - pharmacokinetics (297) 297
cancer (294) 294
abridged index medicus (291) 291
pyrimidines - therapeutic use (290) 290
adolescent (285) 285
dogs (280) 280
double-blind method (280) 280
biological availability (268) 268
chemistry, medicinal (268) 268
hiv infections - drug therapy (268) 268
pharmacology (262) 262
dosage and administration (261) 261
time factors (253) 253
health aspects (242) 242
aged, 80 and over (241) 241
drug administration schedule (240) 240
pyrimidines - administration & dosage (239) 239
kinetics (238) 238
half-life (232) 232
sulfonamides - chemical synthesis (232) 232
toxicology (230) 230
antineoplastic agents - pharmacology (227) 227
internal medicine (222) 222
antineoplastic agents - therapeutic use (218) 218
cross-over studies (217) 217
darunavir (211) 211
clinical trials (208) 208
clinical trials as topic (201) 201
infectious diseases (199) 199
pyrimidines - pharmacology (198) 198
pyrimidines - adverse effects (193) 193
research article (191) 191
apoptosis - drug effects (187) 187
apoptosis (185) 185
chemistry, analytical (181) 181
antineoplastic agents - pharmacokinetics (178) 178
rats, wistar (176) 176
tissue distribution (175) 175
drugs (173) 173
neoplasms - drug therapy (173) 173
cardiovascular system & cardiology (169) 169
cell biology (169) 169
chemistry, multidisciplinary (168) 168
molecular structure (167) 167
biomedicine (164) 164
chromatography, high pressure liquid (164) 164
fluorobenzenes - pharmacokinetics (162) 162
disease models, animal (161) 161
proteins (159) 159
rosuvastatin (158) 158
models, biological (157) 157
protein binding (157) 157
ritonavir - administration & dosage (156) 156
medicine (155) 155
solubility (154) 154
cell proliferation - drug effects (153) 153
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (5197) 5197
Japanese (57) 57
German (45) 45
French (14) 14
Russian (14) 14
Portuguese (8) 8
Spanish (8) 8
Italian (7) 7
Chinese (6) 6
Czech (2) 2
Polish (2) 2
Danish (1) 1
Dutch (1) 1
Finnish (1) 1
Norwegian (1) 1
Romanian (1) 1
Swedish (1) 1
Ukrainian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Clinical and Experimental Pharmacology and Physiology, ISSN 0305-1870, 10/2006, Volume 33, Issue 10, pp. 917 - 924
...)-2-selective NSAIDs is linked to their pharmacokinetics. • A single oral dose of rofecoxib (10 mg/kg), celecoxib (40 mg/kg), meloxicam (3 mg/kg) or placebo was administered to rats... 
pharmacokinetics | kidney | non-steroidal anti-inflammatory drugs | cyclo-oxygenase-2 | sodium urinary excretion | cyclo‐oxygenase‐2 | non‐steroidal anti‐inflammatory drugs | Cyclo-oxygenase-2 | Pharmacokinetics | Kidney | Non-steroidal anti-inflammatory drugs | Sodium urinary excretion | Pharmacology & Pharmacy | Physiology | Life Sciences & Biomedicine | Science & Technology | Thiazoles - blood | Area Under Curve | Thiazines - administration & dosage | Thiazines - adverse effects | Sulfones - adverse effects | Male | Thiazoles - administration & dosage | Anti-Inflammatory Agents, Non-Steroidal - blood | Thiazoles - adverse effects | Thiazoles - pharmacokinetics | Dose-Response Relationship, Drug | Cyclooxygenase 2 Inhibitors - adverse effects | Sulfonamides - blood | Lactones - blood | Lactones - pharmacokinetics | Sodium - urine | Lactones - administration & dosage | Pyrazoles - blood | Pyrazoles - pharmacokinetics | Sulfones - blood | Placebos - administration & dosage | Pyrazoles - adverse effects | Thiazines - pharmacokinetics | Kidney - drug effects | Administration, Oral | Cyclooxygenase 2 Inhibitors - administration & dosage | Rats | Thiazines - blood | Celecoxib | Lactones - adverse effects | Placebos - pharmacokinetics | Sulfones - pharmacokinetics | Cyclooxygenase 2 Inhibitors - pharmacokinetics | Rats, Sprague-Dawley | Sulfonamides - pharmacokinetics | Pyrazoles - administration & dosage | Animals | Anti-Inflammatory Agents, Non-Steroidal - adverse effects | Potassium - urine | Anti-Inflammatory Agents, Non-Steroidal - pharmacokinetics | Sulfonamides - adverse effects | Sulfonamides - administration & dosage | Sulfones - administration & dosage | Kidney, drug effects | Lactones, adverse effects | Sulfones, administration and dosage | Thiazoles, administration and dosage | Anti-Inflammatory Agents, Non-Steroidal, pharmacokinetics | Anti-Inflammatory Agents, Non-Steroidal, adverse effects | Sodium, urine | Thiazines, blood | Anti-Inflammatory Agents, Non-Steroidal, blood | Lactones, administration and dosage | Cyclooxygenase 2 Inhibitors, adverse effects | Pyrazoles, blood | Sulfonamides, pharmacokinetics | Thiazines, pharmacokinetics | Pyrazoles, administration and dosage | Thiazoles, blood | Sulfonamides, administration and dosage | Cyclooxygenase 2 Inhibitors, administration and dosage | Lactones, pharmacokinetics | Sulfonamides, blood | Cyclooxygenase 2 Inhibitors, pharmacokinetics | Thiazines, adverse effects | Lactones, blood | Thiazoles, adverse effects | Thiazoles, pharmacokinetics | Sulfones, blood | Sulfonamides, adverse effects | Thiazines, administration and dosage | Placebos, pharmacokinetics | Sulfones, pharmacokinetics | Pyrazoles, adverse effects | Placebos, administration and dosage | Potassium, urine | Sulfones, adverse effects | Pyrazoles, pharmacokinetics | Index Medicus
Journal Article
Clinical pharmacokinetics, ISSN 0312-5963, 2007, Volume 46, Issue 9, pp. 739 - 756
Journal Article
Journal of Hepatology, ISSN 0168-8278, 2015, Volume 63, Issue 4, pp. 805 - 812
.... The aim of this study was to characterize the effects of mild, moderate, and severe hepatic impairment on the pharmacokinetics of these drugs... 
Gastroenterology and Hepatology | Direct-acting antiviral agents | Ombitasvir | Chronic hepatitis C | Hepatic impairment | Ritonavir | Paritaprevir | Pharmacokinetics | Dasabuvir | Gastroenterology & Hepatology | Life Sciences & Biomedicine | Science & Technology | Antiviral Agents - pharmacokinetics | Humans | Middle Aged | Cytochrome P-450 CYP3A Inhibitors - pharmacokinetics | Male | Anilides - pharmacokinetics | Carbamates - administration & dosage | Hepatitis C, Chronic - complications | Carbamates - pharmacokinetics | Dose-Response Relationship, Drug | Uracil - administration & dosage | Ribavirin - administration & dosage | Ribavirin - pharmacokinetics | Female | Drug Therapy, Combination | Liver Function Tests | Cytochrome P-450 CYP3A Inhibitors - administration & dosage | Ritonavir - administration & dosage | Macrocyclic Compounds - pharmacokinetics | Treatment Outcome | Hepatitis C, Chronic - drug therapy | Antiviral Agents - administration & dosage | Hepatic Insufficiency - blood | Hepatitis C, Chronic - blood | Sulfonamides - pharmacokinetics | Ritonavir - pharmacokinetics | Anilides - administration & dosage | Macrocyclic Compounds - administration & dosage | Hepatic Insufficiency - etiology | Uracil - pharmacokinetics | Sulfonamides - administration & dosage | Uracil - analogs & derivatives | Antiviral agents | Safety and security measures | Hepatitis C virus | Hepatitis C | Index Medicus
Journal Article
03/2000, Volume 38, Issue 3, 18
... Pharmacokinetics and Pharmacodynamics of Celecoxib A Selective Cyclo-Oxygenase-2 Inhibitor Neal M. Davies, 1 Andrew J. McLachlan, 1 Ric O. Day 2 and Kenneth M. Williams 2 1... 
Pregnancy | Celecoxib, drug interactions | Cyclooxygenase inhibitors, pharmacodynamics | Lactation | Celecoxib, pharmacokinetics | Drug interactions | Cyclooxygenase inhibitors, pharmacokinetics | Cyclooxygenase inhibitors, drug interactions | Celecoxib, pharmacodynamics | Pharmacotherapy | Internal Medicine | Medicine & Public Health | Pharmacology/Toxicology | Life Sciences & Biomedicine | Pharmacology & Pharmacy | Science & Technology | Area Under Curve | Cyclooxygenase 2 | Humans | Intestinal Absorption | Anti-Inflammatory Agents, Non-Steroidal - pharmacology | Dose-Response Relationship, Drug | Tissue Distribution | Drug Interactions | Biotransformation | Adult | Female | Anti-Inflammatory Agents, Non-Steroidal - metabolism | Cyclooxygenase Inhibitors - metabolism | Stroke - prevention & control | Prostaglandin-Endoperoxide Synthases - pharmacology | Administration, Oral | Pyrazoles | Cyclooxygenase Inhibitors - administration & dosage | Celecoxib | Sulfonamides - pharmacology | Sulfonamides - pharmacokinetics | Cyclooxygenase Inhibitors - pharmacology | Cyclooxygenase Inhibitors - pharmacokinetics | Membrane Proteins | Cyclooxygenase 2 Inhibitors | Anti-Inflammatory Agents, Non-Steroidal - administration & dosage | Sulfonamides - metabolism | Anti-Inflammatory Agents, Non-Steroidal - pharmacokinetics | Isoenzymes - pharmacology | Myocardial Infarction - prevention & control | Sulfonamides - administration & dosage | Index Medicus
Book Review
1982, ISBN 9783805524483, Volume 31., xi, 224
Book
Journal Article
The lancet oncology, ISSN 1470-2045, 2010, Volume 11, Issue 12, pp. 1149 - 1159
Journal Article
Journal of pharmaceutical sciences, ISSN 0022-3549, 09/2015, Volume 104, Issue 9, pp. 2813 - 2823
Journal Article
Xenobiotica, ISSN 0049-8254, 6/2013, Volume 43, Issue 6, pp. 498 - 508
...) on the pharmacokinetic profile of simvastatin (40 mg single dose) and rosuvastatin (10 mg single dose). 3. In vitro, GSK1292263 demonstrated little/weak inhibition... 
P-glycoprotein | BCRP | transporters | Cytochrome P450 | OATP | dyslipidemia | diabetes | pharmacogenetics | Pharmacogenetics | Dyslipidemia | Transporters | Diabetes | Pharmacology & Pharmacy | Toxicology | Life Sciences & Biomedicine | Science & Technology | Fluorobenzenes - pharmacokinetics | Pyrroles - pharmacokinetics | Simvastatin - adverse effects | Pyrimidines - blood | Humans | Hydroxymethylglutaryl-CoA Reductase Inhibitors - blood | Middle Aged | Male | Heptanoic Acids - adverse effects | Simvastatin - pharmacology | Fluorobenzenes - pharmacology | Young Adult | Drug Interactions | Piperidines - pharmacology | Oxadiazoles - pharmacology | Madin Darby Canine Kidney Cells | Pyrroles - adverse effects | Oxadiazoles - pharmacokinetics | Heptanoic Acids - pharmacology | Mesylates - blood | Troleandomycin - adverse effects | Rosuvastatin Calcium | Mesylates - adverse effects | Pyrimidines - pharmacology | Sulfonamides - pharmacology | Simvastatin - analogs & derivatives | Sulfonamides - pharmacokinetics | Oxadiazoles - adverse effects | Hydroxymethylglutaryl-CoA Reductase Inhibitors - adverse effects | Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacology | Cytochrome P-450 CYP3A - metabolism | Adolescent | Atorvastatin | Pyrimidines - pharmacokinetics | Oxadiazoles - blood | Demography | Heptanoic Acids - pharmacokinetics | Mesylates - pharmacokinetics | Simvastatin - blood | Piperidines - blood | Troleandomycin - pharmacokinetics | Dose-Response Relationship, Drug | Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacokinetics | Sulfonamides - blood | Reference Standards | Adult | Female | Piperidines - pharmacokinetics | Troleandomycin - pharmacology | Fluorobenzenes - blood | Pyrroles - blood | Simvastatin - pharmacokinetics | Pyrroles - pharmacology | Animals | Cytochrome P-450 CYP3A Inhibitors | Mesylates - pharmacology | Piperidines - adverse effects | Dogs | Pyrimidines - adverse effects | Sulfonamides - adverse effects | Aged | Fluorobenzenes - adverse effects | Heptanoic Acids - blood | Index Medicus
Journal Article